The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy.

ABSTRACT: Bladder cancer ranks as the 9th most common type of cancer worldwide. Approximately 70 % of bladder cancers are diagnosed as non-muscle invasive, and they are treated with transurethral resection followed by intravesical therapy. Doxorubicin is one of the effective cytotoxic drugs used in intravesical and systemic therapy, but its cardiotoxicity and nephrotoxicity limit therapeutic dosages. Vorinostat is an anticancer drug used to treat cutaneous T-cell lymphoma, and it demonstrates potent combination effects in various anticancer treatments. We aim to investigate the combined effects and mechanisms of doxorubicin and vorinostat in human bladder cancer cells. Human bladder cancer cells (5637 and BFTC 905) were used in this study. Cell viability of 5637 and BFTC 905 cells decreases in a tim

SUBMITTER: Shen CH 

PROVIDER: S-EPMC11759543 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature